Olena Zaitseva

Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

TNFR2-targeting biologics: Molecular mode of action, possible applications, and future developments.

TNFR2-targeting biologics: Molecular mode of action, possible applications, and future developments.

Journal: Journal of leukocyte biology

Published: October 04, 2025

A simple and broadly applicable nanobody-based approach to generate potent TNFR agonists.

A simple and broadly applicable nanobody-based approach to generate potent TNFR agonists.

Journal: Cell death & disease

Published: August 06, 2025

Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins.

Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins.

Journal: Cell chemical biology

Published: November 30, 2024

A Novel Tetravalent CD95/Fas Fusion Protein With Superior CD95L/FasL Antagonism.

A Novel Tetravalent CD95/Fas Fusion Protein With Superior CD95L/FasL Antagonism.

Journal: Proteins

Published: March 09, 2024

Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.

Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.

Journal: Bioengineered

Published: January 12, 2024

Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling.

Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling.

Journal: Frontiers in cell and developmental biology

Published: July 27, 2023

Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.

Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.

Journal: Frontiers in immunology

Published: March 27, 2023

Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism.

Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism.

Journal: Theranostics

Published: March 17, 2023

Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily.

Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily.

Journal: Frontiers in immunology

Published: December 04, 2022

FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies.

FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies.

Journal: International journal of molecular sciences

Published: September 09, 2022

Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy.

Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy.

Journal: Frontiers in pharmacology

Published: May 03, 2022

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.

Journal: Pharmaceutics

Published: June 01, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026